```html

Wegener’s Granulomatosis (Pulmonary‑Limited)

Overview

Wegener’s granulomatosis, now more commonly called granulomatosis with polyangiitis (GPA), is a rare autoimmune vasculitis that primarily affects small‑ to medium‑sized blood vessels. In the pulmonary‑limited form, the disease is confined to the lungs and upper airway without involvement of the kidneys or other organs.

Who it affects: GPA can occur at any age but most commonly presents in adults aged 40–60, with a slight male predominance. It is more frequent in people of Northern European descent, though cases are reported worldwide.

Prevalence: Overall GPA affects about 1–3 per 100,000 persons. Pulmonary‑limited disease accounts for roughly 15–20 % of all GPA cases, translating to an estimated 0.2–0.6 per 100,000 population.<sup>1</sup> Because the disease is rare and often misdiagnosed as asthma or infection, the true prevalence may be slightly higher.

Symptoms

Symptoms reflect inflammation of the lung tissue, airways, and surrounding structures. They may develop quickly (over weeks) or progress slowly over months.

• Chronic cough – usually dry, but can become productive with blood‑tinged sputum.
• Hemoptysis – coughing up blood; ranges from streaks to larger amounts.
• Dyspnea – shortness of breath that worsens with exertion.
• Chest pain – often pleuritic (sharp, worse with breathing).
• Fever – low‑grade or intermittent.
• Wheezing or noisy breathing – mimics asthma or COPD.
• Sinus symptoms – chronic sinusitis, nasal crusting, epistaxis, or saddle‑nose deformity (if upper airway is involved).
• Ear problems – otitis media or hearing loss due to eustachian tube involvement.
• Fatigue, weight loss, and night sweats – systemic inflammatory response.
• Skin lesions – palpable purpura or ulcers (less common in pulmonary‑limited disease).

Causes and Risk Factors

GPA is an autoimmune disease—the immune system mistakenly attacks blood vessel walls, causing necrotizing granulomas and vasculitis. The precise trigger is unknown, but several factors are implicated:

• ANCA antibodies – particularly proteinase‑3 ANCA (PR3‑ANCA) are present in 80–90 % of active GPA cases and are thought to play a pathogenic role.<sup>2</sup>
• Genetics – Certain HLA‑DRB1 alleles increase susceptibility; familial clustering is rare but documented.
• Environmental exposures – Silica dust, metal fumes, and agricultural dust have been linked to higher risk in epidemiologic studies.
• Infections – Staphylococcus aureus colonization of the nose is associated with higher relapse rates.
• Gender & age – Males slightly more affected; peak incidence in middle age.

Diagnosis

Diagnosing pulmonary‑limited GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often tissue biopsy.

1. Clinical Evaluation

• Detailed history of respiratory symptoms, sinus disease, and systemic signs.
• Physical exam focusing on lung auscultation, nasal examination, and skin assessment.

2. Laboratory Tests

• ANCA testing – ELISA for PR3‑ANCA (c‑ANCA) is the most specific. A positive result supports GPA but is not definitive.<sup>3</sup>
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Inflammatory markers – ESR and CRP are usually elevated.
• Renal function tests – essential to rule out kidney involvement.

3. Imaging

• Chest X‑ray – can reveal nodules, cavitary lesions, or diffuse infiltrates.
• High‑resolution CT (HRCT) – the gold standard for lung assessment; shows multiple nodules (often with a “halo sign”), ground‑glass opacities, and bronchial wall thickening.
• Sinus CT – identifies sinusitis or bony erosion when upper airway symptoms exist.

4. Tissue Biopsy

A lung or bronchial biopsy confirming necrotizing granulomatous inflammation with vasculitis is the diagnostic cornerstone. In pulmonary‑limited disease, bronchoscopy with trans‑bronchial biopsy or CT‑guided percutaneous needle biopsy is commonly performed.

5. Diagnostic Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria give weighted scores for clinical, serologic, and histopathologic features; a cumulative score ≥ 5 classifies the patient as having GPA.<sup>4</sup>

Treatment Options

Treatment aims to induce remission, prevent organ damage, and maintain long‑term disease control. Management is usually overseen by a rheumatologist and a pulmonologist.

Induction Therapy (to achieve remission)

• Glucocorticoids – High‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone pulses (500–1000 mg/day for 3 days) are first‑line.
• Rituximab – Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or two 1 g doses 2 weeks apart. Shown to be non‑inferior to cyclophosphamide with fewer long‑term toxicities.<sup>5</sup>
• Cyclophosphamide – Oral (2 mg/kg/day) or IV (15 mg/kg every 2‑3 weeks) for 3–6 months; reserved for severe disease or when rituximab is contraindicated.

Maintenance Therapy (to keep disease in remission)

• Rituximab – 500 mg every 6 months for 2–4 years (based on relapse risk).
• Aza­zathioprine – 2 mg/kg/day; acceptable alternative for patients unable to receive rituximab.
• Methotrexate – 15–25 mg weekly for patients with mild pulmonary disease and good renal function.
• Low‑dose glucocorticoids – Typically tapered to ≤ 5 mg prednisone daily after 3–6 months.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole prophylaxis (once daily) reduces Staph‑aureus colonization and relapse risk.<sup>6</sup>
• Calcium and vitamin D supplementation + bisphosphonates if long‑term steroids are used.
• Vaccinations: pneumococcal (PCV20), influenza annually, and COVID‑19 boosters (non‑live vaccines are safe).

Procedural Interventions

• Bronchoscopy – For diagnostic biopsy, airway clearance, or managing massive hemoptysis.
• Endobronchial stenting – Rarely required for airway obstruction caused by granulomatous lesions.
• Plasma exchange – Considered only for life‑threatening pulmonary hemorrhage (grade C recommendation).

Living with Wegener’s Granulomatosis (Pulmonary‑Limited)

While GPA is chronic, many patients achieve long‑term remission with modern therapy. Lifestyle adaptations help maintain health and reduce flare risk.

Daily Management Tips

• Medication adherence – Use a pill organizer or smartphone reminders; never stop steroids abruptly.
• Regular follow‑up – Every 3–4 months during remission; labs (CBC, renal panel, ANCA) and chest imaging as directed.
• Monitor symptoms – Keep a diary of cough, sputum, fever, or new sinus issues and share with your provider.
• Stay hydrated – Helps thin secretions and reduces airway irritation.
• Quit smoking – Smoking worsens lung inflammation and interferes with medication effectiveness.
• Exercise safely – Low‑impact aerobic activity (walking, cycling) improves lung capacity; avoid high‑altitude or polluted environments during active disease.
• Stress management – Chronic inflammation can be exacerbated by stress; consider mindfulness, yoga, or counseling.
• Infection prevention – Hand hygiene, avoid close contact with sick individuals, and keep vaccinations up to date.

Support Resources

• American College of Rheumatology (ACR) patient portal.
• Vasculitis Foundation – offers support groups and education materials.
• Local pulmonary rehabilitation programs.

Prevention

Because GPA is largely autoimmune, primary prevention is limited. However, certain measures can lower the chance of relapse or possibly trigger the disease:

• Avoid occupational exposure to silica, coal dust, or metal fumes.
• Promptly treat chronic sinus infections; consider nasal mupirocin if Staph‑aureus colonization is documented.
• Maintain a healthy weight and balanced diet rich in antioxidants (fruits, vegetables, omega‑3 fatty acids).
• Adhere to vaccination schedules to reduce respiratory infections that could precipitate a flare.

Complications

If untreated or inadequately controlled, pulmonary‑limited GPA can lead to serious outcomes:

• Diffuse alveolar hemorrhage – Life‑threatening bleeding into the lungs.
• Permanent lung fibrosis – Reduces vital capacity and causes chronic dyspnea.
• Bronchial stenosis – May require airway dilation or stenting.
• Secondary infections – Due to immunosuppression (pneumonia, opportunistic fungi).
• Medication toxicity – Cyclophosphamide can cause bladder toxicity, infertility, and secondary malignancies; steroids can lead to osteoporosis, diabetes, and hypertension.
• Systemic spread – Approximately 30 % of pulmonary‑limited cases later involve kidneys or other organs.

When to Seek Emergency Care

References

1. Hogan SL, et al. “Epidemiology of granulomatosis with polyangiitis: a systematic review.” Rheumatology (Oxford). 2020;59(9):2205‑2215.
2. Falk RJ, et al. “ANCA‑associated vasculitis.” New England Journal of Medicine. 2022;387:247‑259.
3. Jennette JC, et al. “2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for ANCA‑associated vasculitis.” Arthritis Rheumatology. 2022;74(3):545‑557.
4. Stone JH, et al. “Rituximab versus cyclophosphamide for ANCA‑associated vasculitis.” New England Journal of Medicine. 2010;363:221‑232.
5. Harzallah K, et al. “Trimethoprim‑sulfamethoxazole prophylaxis reduces relapse in GPA.” Annals of Internal Medicine. 2019;171:670‑677.
6. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Updated 2023. Link
7. CDC. “Vaccines for Adults with Immunocompromising Conditions.” 2024. Link

```